2017 Year in Review: Highlights for Lung Cancer
Expert Review
Expert Review

2017 Year in Review: Highlights for Lung Cancer

Expert Review Modules

Not a member of My prIME? Join now for instant access.

This Expert Review features internationally-renowned thought leaders discussing practice-changing data released in 2017 regarding the use of targeted therapy and immunotherapy, as well as molecular testing, in non-small cell lung cancer (NSCLC).

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.5 AMA PRA Category 1 Credits™

Release Date

Release Date

Nov 28, 2017

Expiration Date

Nov 28, 2018

Featured Discussants

  • Tony Mok, MD, FRCP, The Chinese University of Hong Kong, Hong Kong, China
  • Roy S. Herbst, MD, PhD, Yale Cancer Center, New Haven, Connecticut, United States

Featured Topic

Module 1: Advances in Targeted Therapy

Featured Discussants

  • David Planchard, MD, PhD, Gustave Roussy, Villejuif, France
  • Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Module 2: Novel Approaches to Molecular Testing

Featured Discussants

  • Julie Brahmer, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
  • Shirish Gadgeel, MD, University of Michigan, Ann Arbor, Michigan, United States

Featured Topic

Module 3: Immunotherapy for Early-Stage and Locally Advanced NSCLC

Featured Discussants

  • Roy S. Herbst, MD, PhD, Yale Cancer Center, New Haven, Connecticut, United States
  • Heather Wakelee, MD, Stanford University, Stanford, California, United States

Featured Topic

Module 4: Immunotherapy for Metastatic NSCLC

  • Julie Brahmer, MDSidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland, United States
  • Shirish Gadgeel, MDUniversity of Michigan
    Ann Arbor, Michigan, United States
  • Roy S. Herbst, MD, PhDYale Cancer Center
    New Haven, Connecticut, United States
  • Tony Mok, MD, FRCPThe Chinese University of Hong Kong
    Hong Kong, China
  • Geoffrey R. Oxnard, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • David Planchard, MD, PhDGustave Roussy
    Villejuif, France
  • Heather Wakelee, MDStanford University
    Stanford, California, United States

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe findings from recent clinical investigations of immune checkpoint inhibition in lung cancer
  • Evaluate data from studies investigating molecularly targeted agents for specific subgroups of non-small cell lung cancer
  • Incorporate recommendations for diagnostic testing in non-small cell lung cancer into routine practice

This educational activity is supported by grants from AstraZeneca and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

2017 Year in Review: Highlights for Lung Cancer - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.

Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Brahmer has disclosed that she has been a consultant for/received consulting fees from Bristol-Myers Squibb (uncompensated), Celgene Corporation, Lilly, and Merck. She has also performed contracted research for Bristol-Myers Squibb, MedImmune/AstraZeneca, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Gadgeel has disclosed that he has received support for travel to meetings from Genentech/Roche. He has also received research funding from ARIAD/Takeda and AstraZeneca. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Herbst has disclosed that he has received consulting fees from AstraZeneca, Genentech, Lilly, and Merck. He is a member of boards for NextCure, Inc. and SynDevRx, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Mok has disclosed that he has received consulting fees from ACEA Biosciences, Inc.; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; Eli Lilly; geneDecode Co., Ltd.; Ingnyta, Inc.; Merck Serono; MSD; Novartis; OncoGenex Technologies Inc.; Pfizer; Roche/Genentech; SFJ Pharmaceuticals; and Vertex Pharmaceuticals. He performed contracted research for AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eisai, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceuticals, and Taiho. Furthermore, he has ownership interest in Sanomics Ltd. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Planchard has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer, MSD, Novartis, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Oxnard has disclosed that he has received consulting fees from AstraZeneca, Ignyta, Inivata, LOXO, and Takeda. He has also received fees for speaking and teaching from Bio-Rad, Guardant, and Sysmex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wakelee has disclosed that she has been a consultant for/received consulting fees from ACEA, Genentech (uncompensated), Helsinn, Peregrine, and Pfizer. She has also performed research for AstraZeneca/Medimmune, Bristol-Myers Squibb, Celgene, Clovis, Exelixis, Genentech/Roche, Gilead, Lilly, Novartis Oncology, Pfizer, Pharmacyclics, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD, MSc (medical content reviewer) – no relevant financial relationships
  • Amy Furedy, RN (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.